"Designing Growth Strategies is in our DNA"

Critical Care Antiarrhythmic Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Beta Blockers, Calcium Channel Blockers, Sodium Channel Blockers, Potassium Channel Blockers, and Others), By Disease Type (Supraventricular Arrhythmias, Ventricular Arrhythmias, and Others), and Regional Forecast, 2020-2027

Region : Global | Format: PDF | Report ID: FBI104703

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The global critical care antiarrhythmic drugs market size was USD 796.8 million in 2019. The global impact of COVID-19 has been unprecedented and staggering, with critical care antiarrhythmic drugs witnessing a positive demand shock across all regions amid the pandemic. Based on our analysis, the global market will exhibit a stellar growth of 12.9% in 2020. The market is projected to grow from USD 899.8 million in 2020 to USD 1,319.7 million by 2027 at a CAGR of 5.6% in the 2020-2027 period.


The increasing prevalence of cardiovascular disorders across the globe will strongly propel market growth. According to a study published by the American Heart Association (AHA), cardiac disorders are the leading cause of death, accounting for more than 17.6 million deaths in 2016 and more than 23.6 million expected deaths by 2030 globally. Cardiovascular disorders (CVD) and stroke accounted for 14.0% of the total health expenditures in 2014-2015. This is one of the major factors augmenting the critical care antiarrhythmic drugs market growth during the projected timeframe.


Cardiovascular disorders such as atrial fibrillation (AFib) are one of the major conditions leading to irregular heartbeats, referred to as arrhythmia. Hence, the growing incidence of the disorder across the globe will strongly propel market expansion. AFib is the most common arrhythmia diagnosed in clinical practice. For instance, as per the National Center for Chronic Disease Prevention and Health Promotion, it is estimated that 12.1 million people in the U.S. will have AFib by 2030. Also, in 2018, AFib accounted for 175,326 deaths across the U.S. Such factors are responsible for boosting the demand for critical care antiarrhythmic drugs.


Surge in COVID-19 Cases Increases the Risk of Recurrent Cardiac Arrhythmias in Critically Ill COVID Patients


It was originally thought that the novel coronavirus (COVID-19, SARS-CoV-2) was primarily a respiratory disorder, but as larger numbers of patients contracted the virus, many physiological manifestations of the disease are coming to the fore. The impact of COVID-19 goes well beyond the lungs to impact the cardiovascular system and cause complications, such as stroke, shock, heart failure, myocarditis, and arrhythmias.


As Covid-19 cases surge across the globe, the risk of recurrent cardiac arrhythmias in critically ill COVID-19 patients is also high. However, the arrhythmias may stem from cardiac complications and may not be caused by the virus alone. For instance, a study published by the Journal of the American Medical Association (JAMA) states that, in February 2020, 44.4% of the patients assessed from China, Wuhan was treated in intensive care units due to complications related to arrhythmias. Arrhythmias may also be aggravated by severe systemic inflammatory conditions associated with COVID-19. Hence, this factor is likely to have a positive impact on the growth of the critical care antiarrhythmogenic drugs market amidst the pandemic.


LATEST TRENDS


Request a Free sample to learn more about this report.


Increasing Number of Clinical Trials Pertaining to Novel Anti-Arrhythmia Therapeutics is a Prominent Market Trend


The increasing number of new trials conducted recently for treating arrhythmias show improved outcomes and lower rates of hospitalization for patients with novel drug solutions. These clinical trials are being initiated to develop an effective therapeutic framework for atrial fibrillation drug development. For instance, in August 2020, a pilot and feasibility study was conducted at the Vanderbilt University Medical Center (U.S.), where the enrolled patients with frequent symptomatic episodes of atrial fibrillation were observed and analyzed in a cross-over study testing two different classes of antiarrhythmic drugs (AADs). This study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common atrial fibrillation genetic risk allele modulates response to different AADs.


DRIVING FACTORS


Rising Adoption of Antiarrhythmic Drugs in Intensive Care Units (ICUs) Will Support Market Growth


One of the major factors supporting the growth of the critical care antiarrhythmic drugs market is the growing adoption of these therapeutics in intensive care units for the treatment of patients with acute arrhythmias. As per the National Center for Biotechnology Information (NCBI), atrial fibrillation is frequently observed in medical intensive care units (MICU), with up to 30% of MICU patients showing periods of atrial fibrillation. Cardiac arrhythmias are a common complication in ICUs, with reported rates as high as 40%. Many of the common disorder states seen in critically ill patients, including cardiac and pulmonary disease, are risk factors for the development of arrhythmias, making recognition and management in the ICU vitally important. This is one of the most prominent factors expected to augment market growth across the forecast period.


RESTRAINING FACTORS


Side Effects Associated with Antiarrhythmic Drugs Might Restrict Market Growth


Adverse effects associated with antiarrhythmic drugs might act as a growth hampering factor for the market. Quinidine, procainamide, mexiletine, flecainide, and propafenone are all class I antiarrhythmic drugs used for the treatment of various atrial and ventricular arrhythmias.


Despite the benefits of these drugs, there are certain side effects associated with the use of antiarrhythmic medications, such as cardiovascular toxicity, central nervous system toxicity, gastrointestinal symptoms, immune-mediated reactions, and few others. As a result, these undesirable effects may significantly restrict market potential.


SEGMENTATION


By Drug Class Analysis


To know how our report can help streamline your business, Speak to Analyst


Beta Blockers Segment to Dominate Supported by Growing Applications


Based on Drug Class, the global market is categorized into beta blockers, calcium channel blockers, sodium channel blockers, potassium channel blockers, and others.


Among them, the beta-blockers segment held the major market share in 2019. The segment’s dominant share is attributable to the fact that a growing number of research trials are being conducted across the globe to evaluate the efficacy of these drugs in treating arrhythmias. For instance, in November 2016, GlaxoSmithKline announced the initiation of a research study for the evaluation of the efficacy and safety of Lovaza (Omega-3-Acid Ethyl Esters) beta blocker in recurrent, symptomatic atrial fibrillation.


The potassium channel blockers segment, on the other hand, is estimated to witness lucrative growth over the forecast period. This is due to the fact that these drugs are highly effective in treating atrial fibrillation and related arrhythmias. The increasing investments in research and development activities for the development of novel biologics will support the growth of the market in the coming years.


By Disease Type Analysis


Supraventricular Arrhythmias Segment to Hold Largest Market Share


In terms of disease type, the supraventricular arrhythmias segment held the leading market share in 2019. The high share of the segment is majorly supported by the growing prevalence of the condition across the globe. For instance, according to data from the World Health Organization (WHO), as of 2018, atrial fibrillation and atrial flutter were the most common subtypes of supraventricular arrhythmias, affecting approximately 6 million patients in the U.S.


The ventricular arrhythmias segment held a considerable market share in 2019. The segment is poised to experience a positive growth trajectory during the forecast period, owing to the increasing number of cases of the disorder worldwide. Moreover, with the increasing prevalence of the disorder, the demand for biologics pertaining to ventricular arrhythmias has spiked, thereby augmenting segmental growth.  


REGIONAL INSIGHTS


North America Critical Care Antiarrhythmic Drugs Market Size, 2019 (USD Million)

To get more information on the regional analysis of this market, Request a Free sample


The market size in North America stood at USD 359.2 million in 2019. The increasing number of clinical trials pertaining to the development of novel antiarrhythmic drugs, especially in the U.S., is one of the major growth propelling factors. Moreover, the growing number of drug launches across the region will further support the regional expansion of the critical care antiarrhythmic drugs market. For instance, in June 2016, Mylan N.V. announced the U.S. launch of Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, 425 mg, a generic version of GlaxoSmithKline's Rythmol SR, which is indicated to prolong the time for the recurrence of symptomatic atrial fibrillation (AF) in patients with episodic AF who do not have structural heart disease.


Europe is projected to be the second-largest region in terms of market share and revenue. This is attributable to the rapidly rising geriatric population, along with an increasing number of cardiac issues, a large number of manufacturers, and favorable reimbursement policies.


The market in Asia Pacific is likely to expand at a significantly high growth rate. The rising number of government initiatives to raise awareness among the population about the ill effects of prolonged atrial fibrillation is strongly supporting the regional growth of the market.  


Increasing healthcare spending, growing penetration of market players, and a rising number of pilot studies being conducted in the region to evaluate the access to arrhythmia drug treatment among patients are the factors propelling market growth in Latin America and the Middle East & Africa.


KEY INDUSTRY PLAYERS


Sanofi, Pfizer, and Mylan N.V. to Dominate Supported by Increasing Number of Strategic Partnerships


The critical care anti-arrhythmic drugs market is considerably consolidated in nature, with major players, such as Sanofi, Pfizer, Mylan N.V., etc., accounting for a major portion in the industry. Sanofi was the dominant player operating in the antiarrhythmic drugs industry in 2019. The company has been continuously holding a strong position in the cardiovascular drugs industry. This is attributable to several factors, such as novel biologics launches, a robust distribution network across the globe, and a strong focus on mergers and partnerships with major pharmaceutical organizations. For instance, in February 2018, AnaBios announced a partnership with Sanofi to develop a new treatment for atrial fibrillation. The program will focus on compounds designed to modulate a novel cardiac ion channel target.


LIST OF KEY COMPANIES PROFILED:



  • Pfizer Inc. (New York, U.S.)

  • Novartis AG (Basel, Switzerland)

  • Mylan N.V. (Pennsylvania, U.S.)

  • Baxter International Inc. (Deerfield, U.S.)

  • Sanofi (Paris, France)

  • GlaxoSmithKline plc (London, U.K.)

  • Mayne Pharma (Salisbury South, Australia)

  • Upsher-Smith Laboratories, LLC. (Minnesota, U.S.)

  • Amomed Pharma GmbH (Vienna, Austria)

  • Other Prominent Players


KEY INDUSTRY DEVELOPMENTS:



  • September 2020 Beximco Pharmaceuticals Limited, a fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, received the U.S. Food and Drug Administration's (FDA) approval for flecainide acetate tablets for the treatment of arrhythmia.

  • June 2020 – ANI Pharmaceuticals, Inc. announced the launch of Mexiletine Hydrochloride Capsules USP, 150mg, 200mg, and 250mg, for the effective treatment of ventricular arrhythmias, such as sustained ventricular tachycardia.


REPORT COVERAGE


An Infographic Representation of Critical Care Antiarrhythmic Drugs Market

To get information on various segments, share your queries with us



The critical care antiarrhythmic drugs market research report provides a detailed analysis of the market and focuses on key aspects, such as leading companies, drug classes, and disease types. Besides this, it offers insights into the current market trends and highlights key industry developments. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the growth of the market over recent years.


Report Scope & Segmentation









































 ATTRIBUTE



  DETAILS



Study Period



  2016-2027



Base Year



  2019



Forecast Period



  2020-2027



Historical Period



  2016-2018



Unit



  Value (USD million)



Segmentation



By Drug Class



  • Beta Blockers

  • Calcium Channel Blockers

  • Sodium Channel Blockers

  • Potassium Channel Blockers

  • Others



By Disease Type



  • Supraventricular Arrhythmias

  • Ventricular Arrhythmias

  • Others



 



By Geography



  • North America (By Drug Class, By Disease Type, and by Country)

  • Europe (By Drug Class, By Disease Type, and by Country)

  • Asia Pacific (By Drug Class, By Disease Type, and by Country)

  • Latin America (By Drug Class, By Disease Type, and by Country)

  • The Middle East & Africa (By Drug Class, By Disease Type, and by Country)



Frequently Asked Questions

Fortune Business Insights says that the global critical care antiarrhythmic drugs market size stood at USD 796.8 million in 2019 and is projected to reach USD 1,319.7 million by 2027.

In 2019, the market value stood at USD 796.8 million.

The market will exhibit decent growth at a CAGR of 5.6% during the forecast period (2020-2027).

By drug class, the beta blockers segment will be the leading segment in the market.

The increasing prevalence of cardiac disorders, the growing number of clinical trials, rising geriatric populations, and a high willingness to spend on anti-arrhythmia drug research are the key drivers of the market.

Sanofi, Pfizer, and Mylan N.V. are the top players in the market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
Critical Care Antiarrhythmic Drugs Market Size, Share and Global Industry Trend Forecast till 2026
  • Jan, 2021
  • 2019
  • 2016-2018
  • 132

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X